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Abstract
Morning symptoms of rheumatoid arthritis (RA) are linked to circadian increase of night inflammation, suppor-
ted by inadequate cortisol secretion in active disease. Therefore, exogenous glucocorticoid administration in RA 
is recommended by EULAR and ACR from the beginning of the diagnosis, since may partially act like a “replace-
ment therapy”. In addition, the prevention/treatment of the night up-regulation of the immune/inflammatory 
reaction has been shown more effective when exogenous glucocorticoid administration is managed with a ni-
ght-time-release formulation.
Despite a considerably higher cost than conventional prednisone (immediate release), chronotherapy with ni-
ght-time-release prednisone has been recognized a cost-effective option for RA patients not on glucocorticoids 
who are eligible for therapy with biologic disease-modifying antirheumatic drugs (DMARDs). Interestingly, since 
different cell populations involved in the inflammatory process are particularly activated during the night (i.e. 
monocytes, macrophages), other therapeutical approaches used in RA, such as conventional DMARDs and non-
-steroidal anti-inflammatory drugs (NSAIDs) should follow the same concepts of glucocorticoid chronotherapy. 
Therefore, bedtime methotrexate chronotherapy was found to better manage RA symptoms, and several availa-
ble NSAIDs (i.e. indomethacin, aceclofenac, ketoprofen, flurbiprofen, lornoxicam) have been recently modified 
in their formulation, in order to obtain more focused night action. 
Key words: rheumatoid arthritis, circadian rhythms, glucocorticoids, chronotherapy, disease-modifying antir-
heumatic drugs, non-steroidal anti-inflammatory drugs, rheumatic diseases.
Introduction
The crucial clinical signs and symptoms of rheuma-
toid arthritis (RA) vary within a day as well as between 
days, and in particular the morning joint stiffness that is 
present in almost all patients with active RA is consid-
ered one of the most characteristic  diagnostic criteria 
of the disease [1]. 
On the other hands, other RA symptoms, that include 
joint pain and functional disability are commonly most 
severe in the early morning and restart following 24-h 
cycles [2]. The circadian rhythms of the disease are con-
sequence of altered immune/inflammatory and neuro-
endocrine activities [2]. 
Since the night activation of the immune-inflamma-
tory reaction is a common pathway, it is not surprising 
that also in other chronic inflammatory rheumatic dis-
eases, like polymyalgia rheumatica (PMR) and ankylos-
ing spondylitis, the symptoms of joint pain and stiffness 
typically are most evident during the early morning [3]. 
In synthesis, the morning symptoms, are linked to 
the circadian increase of proinflammatory mediators 
especially cytokines, as result of an increased night in-
flammation, at least in RA. 
Cytokines, such as tumor necrosis factor α (TNF-α) 
or interleukin 6 (IL-6) are highly effectively increased in 
patients with active RA in the very late night, whereas 
on the contrary are detectable at very low levels after 
12 am [4]. 
It is now well assessed that circadian  rhythms play 
an important role in RA symptomatology and both are 
linked to the pathophysiology of the disease [5, 6].
Among the triggers/enhancers for the increased 
cell release and serum concentrations of cytokines, are 
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recognized the proinflammatory night hormones, such 
as melatonin (and prolactin), that follow theirself a 24-
hour daily cycle, as well as full availability of bioenergies 
during the night [7, 8] (Fig. 1). 
In addition, the nocturnal capability of the neuroen-
docrine system to determ an intense inflammatory re-
sponse with related clinical effects, seems also realized 
in acute inflammatory events such as the gout attack.
The “clock”of circadian rhythms and 
rheumatoid arthritis
In normal conditions and in all individuals, a circadi-
an clock drives rhythms that are necessary to synchro-
nise almost all the human functions according to  the 
24-hour environment [9].
Indeed, the most evident physiological functions un-
der circadian control include the sleep-wake cycle, body 
temperature, blood pressure, heart rate, as well as endo-
crine regulation (i.e. adrenal and gonadal steroidogene-
sis)  and in particulat the immune response. 
Daily rhythms are controled by a central nervous sys-
tem pacemaker, which is found in a hypothalamic region 
located above the optic chiasm and called the suprachi-
asmatic nucleus (SCN) [10] (Fig. 2). 
Therefore, the SCN collects from the eyes the light 
inputs via the retinohypothalamic tract and  the central 
pacemaker synchronises with other and additional perif-
eral pacemakers found locally within organs, tissues and 
cells [10]. Interestingly, these “periferal clocks” are syn-
chronised by the “central clock”, however, at the same 
time, they are self-sustaining and can be entrained by 
external stimulators such as temperature changes.
Recently, a bi-directional interaction between the in-
flammatory reaction and the circadian clock has been 
shown. The disruption of the clock has a significant ef-
fect on the efficiency of the immune system, with im-
pact on the pathogenesis of RA. On the contrary, the 
inflammatory reaction can directly alter cellular expres-
sion of clock genes [11]. 
Several possible disruptors of the clock have been 
identified and  include for example the  jet-lag, causing 
a de-synchrony between the internal clock and the envi-
ronment, as well as the condition of night shift-workers.
In general, constant and frequent shifts in the dai-
ly schedule are strongly detrimental to health and have 
been implicated for an increased incidence of chronic 
diseases such as diabetes, irritable bowel syndrome, 
cardiovascular disease, metabolic syndromes and even 
cancer [12]. As matter of fact, a recent study showed 
a significant link between shift work and an increased 
risk of RA, especially in women [13].
The endocrine system mediates the diffusion of tim-
ing signals from the SCN throughout the body and to the 
immune system, having as circadian agents two night 
hormones, namely melatonin (prolactin) and glucocorti-
coids. Both hormones are now recognized crucial in regu-
Fig. 1. The circadian sequence of nocturnal hormone secretion that induce activation (melatonin, prolactin) 
and/or down regulation (cortisol) of the immune inflammatory response, during the night, determine the 
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lation of the immune/inflammatory response, and there-
fore contribute to the pathogenesis of RA [14, 15] (Fig. 2).
The endogenous glucocorticoid 
production in rheumatoid arthritis
Generally, acute inflammatory events such as a bac-
terial infections, activate the response of the hypotha- 
lamus–pituitary–adrenal (HPA) axis leading to increas- 
ed circulating ACTH and cortisol for a short period of 
time [16]. 
From the other side, the inflammation-associated 
down regulation of the HPA axis activity in chronic con-
ditions such as in RA, depends on both to circulating cy-
tokines that can damage the HPA axis functions on all 
levels (hypothalamus, pituitary gland and adrenal gland) 
and to a consequent and partial adrenal subclinical in-
sufficiency [17] (Fig. 2).
The proinflammatory cytokines IL-1β and TNF are 
the main factors, which interfere with several steps of 
steroidogenesis and the inadequate secretion of endog-
enous glucocorticoids is also detectable by studying se-
rum levels of cytokines and steroids during the circadian 
rhythms. 
Interestingly, the circadian rhythm of serum cortisol 
with respect to amplitude and period is similar in both 
healthy controls and in RA patients having a mild or 
moderate disease. On the contrary serum levels of IL-6 
are at least ten times higher as well as the circadian 
rhythm is quite different in healthy controls versus RA 
patients. 
However, despite the raised serum concentrations of 
IL-6 in RA active disease, the amplitude of the circadian 
rhythm of cortisol is not increased as should be expect-
ed. This condition confirms an of inadequate cortisol 
secretion in presence of adrenal stress that in turn is 
related to persistent active disease [18] (Fig. 2). 
Fig. 2. The daily neuroimmunoendocrine rhythms (gonadal, adrenal, pituitary hormones)  are controlled by 
a central pacemaker, which is found in a hypothalamic region called the suprachiasmatic nucleus (SCN) of 
the central nervous system (CNS).  Basically melatonin increases and cortisol reduces the Immune/inflam-
matory reaction following a circadian rhythm.
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In addition, the degradation of the bioactive cortisol 
to the biologically inactive cortisone it has been shown 
increased when studying mixed synovial cell popula-
tions originated by the inflamed tissue. This phenom-
enon has been found due to increased numbers of pos-
itive cell for the degrading enzyme 11β-hydroxysteroid 
dehydrogenase (type 2) and to a decreased reactivation 
of cortisone to cortisol [19]. 
As matter of fact, the clinical improvement observed 
in RA patients after glucocorticoid therapy appeared in 
a previous study, to be attributed to a direct dampening 
of pro-inflammatory factors, as well as to the restoration 
of the steroid milieu [20]. 
In conclusion, since cortisol is considered the most 
potent endogenous anti-inflammatory substance, its 
pathological downregulation and hyposecretion during 
the night, justify the appearance of the early morning 
clinical symptoms in RA patients, while in contrast the 
perseverant synthesis of melatonin may continous to 
enhance the night inflammatory reaction [20].
The production and the role of melatonin 
in rheumatoid arthritis
Melatonin (nocturnal pineal gland hormone) exerts 
a variety of actions on the immune system. Like cortisol, 
melatonin production follows a circadian rhythm, but ac-
tivates immune cells and enhances inflammatory cyto-
kine and nitric oxide [5, 21].
Previous investigations have shown that in both in 
healthy subjects and RA patients, melatonin levels in-
crease progressively from 8 pm to the early morning 
hours and in RA patients they reach peak levels at mid-
night, which was at least 2 hours earlier than in healthy 
controls [21].
Consequently, in RA patients, melatonin concentra-
tions reach a plateau that last for 2–3 hours and that is 
not observed in controls whereas, after 2 am, melatonin 
levels decrease similarly both in healthy subjects and in 
RA patients. 
Most detailed investigations, confirmed that the noc-
turnal rhythm of melatonin occurs also in RA patients, but 
with an earlier nocturnal peak and a with a longer dura-
tion in the early morning [5, 21].
Indeed,  the production of several cytokines, like IL-1, 
IL-6, tumour necrosis factor α (TNFα), IFN-γ, IL-2, and IL-12 
(Th1 cytokines) reach their peak during the night, shortly 
later the melatonin serum levels are highest and plasma 
cortisol is lowest.
Of real interest, melatonin was found detectable and 
in high concentration in synovial fluids from RA patients, 
and binding sites for melatonin were found present in 
synovial macrophages [22]. In addition, cultured RA syno-
vial macrophages react to melatonin stimulation with an 
increased production of proinflammatory cytokine [23]). 
In conclusion, it is not surprising that melatonin admin-
istration does not improve RA clinical status, but on the 
contrary may further enhance the nocturnal inflammato-
ry reaction as previously showed [24].
Low-dose glucocorticoids and 
chronotherapy in rheumatoid arthritis 
The treatment with exogenous glucocorticoids (i.e. 
prednisone) is today recommended at low doses in RA 
since may act like a “replacement therapy” in presence 
of decreased endogenous cortisol availability, as previ-
ously discussed [25, 26].
Clearly, important aspects still differentiate between 
exogenous (i.e. therapeutic) and endogenous (i.e. phys-
iologic) glucocorticoids, especially regarding different 
mineralocorticoid and glucocorticoid activities [25]. 
As matter of fact, exogenous synthetic glucocorti-
coids exert a more selected glucocorticoid/antiinflam-
matory action (less mineralcorticoid effects), as well 
as have different plasma kinetics, metabolism, biologic 
half-life and (nongenomic) high-dose effects compared 
to cortisol (or hydrocortisone).
However, in any case, the long-term administration 
of exogenous glucocorticoid may interfere with the HPA 
axis function and as consequence with the circadian 
cortisol (endogenous) production. 
A recent analysis considering  the period 1980–2004 
and regarding the long-term glucocorticoid therapy in 
RA, has shown in the last decades, a progressive reduc-
tion of mean initial low-dose from 10.3 up to 3.6 mg/day 
(prednisone) [27].
The more specific items of the EULAR recommenda-
tions for the management of RA relate, when starting 
disease-modifying antirheumatic drug (DMARD) thera-
py in early disease, to use a conventional DMARD strat-
egy in combination with (low) doses glucocorticoids 
[28]. This approach (low dose glucocorticoids) has been 
approved very recently and suggested also in the new 
guide lines of the ACR [29].
As matter of fact, in agreement with the conventional 
definition of DMARD, there is evidence that glucocorti-
coid therapy in RA, especially long-term low-dose treat-
ment, may in addition slow radiographic progression by 
at least 50% when given to patients with early disease.
Since glucocorticoids exert crucial genomic effects 
on cellular immunity and given the presence of the cel-
lular circadian rhythms, therefore, the prevention of the 
pathological nocturnal up-regulation of immune cell ac-
tivity (and related increased production of cytokines), 
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may be not optimal with their exogenous administra-
tion betwen 6.00 and 8.00 since too late [30]. 
Since it is well evident that RA symptoms like pain, 
stiffness and functional disability show maximum level 
in the early morning hours, it is now also evident that 
preventing the nocturnal rise of proinflammatory cy-
tokines by night glucocorticoids is more effective than 
treating established symptoms in the morning [31].
Finally, in RA, several inflammatory pathways in-
volving also the central nervous system (i.e. involved in 
pain perception), might be better controlled by the cor-
rect chronotherapy and have been shown to result on 
increased sleep quality and also reduction of depressive 
symptoms [6].
Therefore, in 1964 was published the first reliable clin-
ical study showing the superiority of night versus morn-
ing administration of glucocorticoids in RA [32]. In detail, 
fifty-six RA patients were included in a double-blind trial 
and none of patients had at any time taken a dose of glu-
cocorticoids superior to 5 mg prednisolone. For each RA 
patient the 4-week trial was divided into 2-week periods 
and RA patients received one tablet at 10 pm (5 mg pred-
nisolone) and a second tablet-placebo, in the morning. As 
result the 5 mg prednisolone administered at night was 
found to reduce or eliminate morning stiffness in a supe-
rior manner in the majority of RA patients. The effect was 
fast and, according to the study design, it was confirmed 
by altering in the patients the time of administration from 
night to morning and vice versa in random style and un-
der double-blind method [32].
Twenty years later (1984), a further study involved 
41 RA patients treated with low-dose prednisolone 
(mean 5.8 mg) and again included in a double-blind 
cross-over study with the intention to establish the ef-
fect of timing (morning or night) of prednisolone dosage 
on morning symptoms (especially stiffness) [33]. 
The RA patients received prednisolone (70% = or 
< 5 mg/day) on the late evening (10–11 pm) and on ris-
ing (6–7 am) and once again prednisolone given at night 
induced a significantly shorter duration of morning stiff-
ness (p = 0.0001) versus the equivalent dose given in 
the morning. In addition, a significant patient preference 
(p < 0.05) for the night therapy using the non-paramet-
ric statistical analysis (sign test).
In 1997, 26 RA patients glucocorticoid-naive, were in 
random manner tested into two equal groups and treat-
ed with to low doses of prednisolone at either 2.00 am 
or 7.30 am [34]. 
Again low doses of prednisolone (5 or 7.5 mg daily) at 
2.00 am after only 5 days showed superior efficacy on the 
duration of morning stiffness (p < 0.001), Lansbury index 
(p < 0.001), Ritchie index (p < 0.001), joint pain (p < 0.001) 
and morning serum concentrations of IL-6 (p < 0.01). 
Interestingly, the other study group, showed minor 
effects, even if significant, on morning stiffness (p < 
0.05) and circulating concentrations of IL-6 (p < 0.05).
More recently, using a most advanced approach for 
the low-dose prednisone chronotherapy in RA patients 
included the modified-release prednisone, consisting in 
a timing drug release with administration at 10 pm and 
release around 2–3 am [35].
Large-scale trials in RA patients documented that 
modified-release prednisone has superior efficacy for 
long-term low-dose glucocorticoid treatment, showing 
a significant reduction in morning joint stiffness/fatigue 
and a similar safety profile but without any additional 
suppression of the HPA axis [36, 37].
All the investigations confirmed that the specif-
ic timing of exogenous prednisone availability, linked 
to the interaction between IL-6 and the HPA axis, may 
correct in RA a postulated deficiency regarding the HPA 
control [38].
Management results from  
the glucocorticoid chronotherapy 
in rheumatoid arthritis
Recent single-center crossover studies were con-
ducted in RA patients in order to compare the pharma-
cokinetics of a single 5 mg oral dose of modified-release 
prednisone and conventional prednisone [39].
No significant differences in pharmacokinetic param-
eters of both formulations apart from the programmed 
delay in release of prednisone from the night-time-re-
lease formulation were detected. 
The effects on the HPA axis of long-term low-dose 
chronotherapy with modified-release prednisone have 
been carefully investigated in RA patients [40]. The in-
crease of cortisol plasma concentrations after injec-
tion of corticotropin-releasing hormone (CRH) was 5.5 
(SD 4.37) μg/dl on regular-morning prednisone after 
3 months and 5.3 (4.07) μg/dl on modified-release pred-
nisone at 12 months. 
In addition, no worsening of adrenal impairment 
was found on treatment with night-time-release pred-
nisone in RA patients with low responsiveness to CRH 
testing before the treatment with such approach.
Interestingly, an observational study assessed func-
tional ability in RA patients treated with modified-re-
lease prednisone under conditions of normal clinical 
practice [41] and the dose of prednisone was significant-
ly reduced after 9 months of treatment (from 5.0 to 4.4 
mg/day, p < 0.001) with modified-release prednisone, 
as well as fewer RA patients required biological DMARD 
treatments.
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To assess if modified-release prednisone adminis-
tered at bedtime is confirmed more efficient than pred-
nisone administered in the morning, a total number of 
950 RA outpatients treated with different glucocorti-
coids and DMARDs (10.5% leflunomide, 83.7% metho-
trexate, 15.8% biologics) were switched from morning 
prednisone or 6-methyl (6M)-prednisolone to low-dose 
modified-release prednisone and were followed for 
4 months [42].
In particular, 513 RA patients were switched to mod-
ified-release prednisone from morning prednisone (9.4 
±5.4 mg) and 437 from 6M-prednisolone (6.7 ±3.7 mg). 
After 4-months (904, 96.8%) of modified-release pred-
nisone treatment following the switch from morning 
prednisone or 6M-prednisolone, patient and physician 
global assessment, morning stiffness duration and pain 
intensity improved significantly (p < 0.001) when com-
pared to basal time. Finally, mean daily modified-release 
prednisone doses also decreased from 8.2 mg to 6.7 mg 
between baseline and the check at 4 months.
It was observed that glucocorticoid-naive RA pa-
tients seem the best responders to the night-time-re-
lease prednisone, however, whereas switching from 
other glucocorticoids to low dose modified-release 
prednisone it seems to improve significantly outcomes 
especially after 4 months, as reported in the open, 
un-blinded study [42].
To confirm these studies, in a very recent investigation 
assessing the efficacy and safety of night-time-release 
prednisone versus morning prednisone in newly diag-
nosed polymyalgia rheumatica (PMR) patients, there was 
a clear consistent trend for a significantly stronger effect 
of modified-release prednisone across most secondary 
efficacy endpoints at week 4, with a evident treatment 
differences observed already at week 1 [43].
Of note, night-time-release prednisone reduced IL-6 
concentrations more significantly in morning-release 
prednisone treated patients (p < 0.01).
Cost-effectiveness of modified-release formulations 
compared with immediate-release prednisone has been 
also evaluated [44]. Health benefits were evaluated as 
quality-adjusted life years (QALYs) and the final output 
was the incremental cost-effectiveness ratio (ICER). 
As expected, mean treatment costs per patient 
were found higher for night-time-release than for im-
mediate-release prednisone. In particular, the analysis 
showed that mean treatment costs per patient per year 
is higher for modified release-prednisone (£ 649.70) 
than for regular prednisone (£ 46.54).
On the other hands, the model generated an incre-
mental QALY of 0.044 in favor of modified-release pred-
nisone which resulted in an ICER of £ 13,577.
Probabilistic sensitivity analysis showed that mod-
ified release-prednisone induces an 84% probability 
of being cost-effective if there is a willingness-to-pay 
threshold of £ 30,000 per QALY.
Another study on cost-effectiveness, analyzed the 
effects of a 12-week treatment with modified-release 
prednisone versus placebo on the costs of drug treat-
ment of RA [45]. The study concluded that 11–13% more 
patients on modified-release prednisone than on place-
bo dropped below reimbursement thresholds for the UK, 
Belgium and Netherlands and assuming 1 year of bio-
logics cost € 15,000 and MR-pred costs € 1/day, almost 
€ 396 are saved in each RA patient since delaying biolog-
ic treatment by 12 weeks. 
Other approaches to chronotherapy 
in rheumatoid arthritis 
Different cells involved in the inflammatory pro-
cess (i.e. monocytes that loose their normal circadian 
rhythms) are particularly activated during the night, 
therefore, other therapeutical approaches used in RA, 
for example with non- steroidal anti-inflammatory drugs 
(NSAIDs) and DMARDs should follow the same concepts 
of glucocorticoid chronotherapy [46].
Of note, the circadian activation of the cells involved 
in the RA immune/inflammatory process represent 
the preferential target for conventional and biologic 
DMARDs, and the administration of anti-proliferative 
drugs (i.e. methotrexate, leflunomide, cyclophospha-
mide etc.) should be adapted to those rhythms.
This possible approach was tested in an in vivo in-
vestigation using an animal model of arthritis, and con-
firmed that the optimal dosing time for the methotrex-
ate anti-inflammatory action and decrease of TNF-α, 
should be associated when adapting to the 24-h cycling 
of TNF-α, itself [47]. 
A further clinical study has suggested that bedtime 
methotrexate chronotherapy (3 times a week once a day 
the evening) can better improve RA symptoms com-
pared to the current standard dosing methods [48].
Interesting, the migration/activation of neutrophilic 
polymorphonuclear in the inflammatory areas, follows 
night rhythms and starting early in the 1980s, various 
controlled-release NSAIDs have been explored for ad-
ministration-time differences in their symptomatic ef-
fects [49].
An early double-blind, crossover study design that in-
cluded multiple (4 to 6 times per day) pain, stiffness, and 
hand strength self-assessments in RA patients, showed 
that a twice-daily flurbiprofen schedule (i.e. 200 mg in 
the morning and 200 mg at midday) was less effective 
in modulating morning RA signs and symptoms than 
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ones that included bed time administration (200 mg 
in the morning and 200 mg at bedtime or 200 mg at 
midday and 200 mg at bedtime) [50]. 
A further study, found that evening once-daily sched-
uling of 75 mg (indomethacin formulation 25 mg immedi-
ate-release combined with 50 mg controlled-release) re-
sulted in a more efficient control of morning OA symptoms 
compared to once-daily morning or once-daily midday [51].
Interestingly, a pH-responsive dual pulse multipartic-
ulate dosage compund containing ketoprofen, was test-
ed in RA and was found able to control circadian symp-
toms during midnight and early morning [52].
In addition, with the main intent of delivering max-
imum concentration of indomethacin in the night, an 
oral compression coated tablet was developed with 
a lag time of 6 hours, before immediate release [53].
Further results should be obtainable in chronophar-
macological treatment of morning RA symptoms with 
a new synthesized eudragit-coated aceclofenac-loaded 
pectin microspheres or even with with a pH-triggered 
delayed-release colon-specific aceclofenac micro-
spheres [54, 55].
Finally, a formulation of mini-tablets-filled-pulsincap 
delivering lornoxicam for chronotherapy of RA was syn-
thesizedfor the night administration [56]. The optimized 
pulsincap formulation releases lornoxicam after a lag 
time of 5 hrs with maximum amount of the drug avail-
able in the early morning.
In conclusion, the recent research on biological 
rhythms in inflammation and the synthesis of “circa-
dian”drugs, is leading to a better understanding of the 
mechanisms of inflammation and to an optimal use of 
the drugs in RA [57, 58].
Conclusions
The stiffness and functional joint disability charac-
terizing the early morning hours in RA patients, is relat-
ed to the night activation of the immune/inflammatory 
response.
The prevention/treatment of the immune cell activity 
(and related flare of cytokine synthesis and other media-
tors) has been shown more effective when the availabil-
ity of the exogenous glucocorticoids is obtained in the 
middle of the night. The very positive results obtained 
in RA patients treated with modified-release prednisone 
for the low dose chronotherapy, and following the chro-
nobiology of the disease, seem applicable even for other 
agents such as conventional DMARDs and NSAIDs.
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